Mabvax Therapeutics Holdings Inc  

(Public, OTCMKTS:TELK)   Watch this stock  
Find more results for NASDAQ:TELK
1.10
Delayed:   3:43PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.68 - 2.15
Open     -
Vol / Avg. 0.00/17,270.00
Mkt cap 15.33M
P/E     -
Div/yield     -
EPS -1.00
Shares 13.93M
Beta 0.11
Inst. own 3%

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -334.49% -126.97%
Return on average equity - -221.75%
Employees 22 -
CDP Score - -

Address

11588 Sorrento Valley Rd Ste 20
SAN DIEGO, CA 92121-1336
United States - Map
+1-858-2599405 (Phone)
+1-650-8457800 (Fax)

Website links

Description

MabVax Therapeutics Holdings, Inc., formerly Telik, Inc. (Telik), is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company´┐Żs drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. In July 2014, Telik Inc announced that MabVax Therapeutics merged with a wholly owned subsidiary of Telik Inc and became a wholly owned subsidiary of Telik Inc.

Officers and directors

Michael M. Wick M.D., Ph.D. Chairman of the Board
Age: 67
J. David Hansen President, Chief Executive Officer, Director
Gregory P. Hanson Chief Financial Officer
Wendy K. Wee Principal Accounting Officer, Vice President - Finance, Controller
Age: 60
Philip O. Livingston M.D. Chief Science Officer, Director
William P. Kaplan Esq. Vice President, General Counsel, Corporate Secretary, Vice President - Legal Affairs
Age: 59
Wolfgang W. Scholz Ph.D. Vice President - Antibody Discovery
Steven R. Schow Ph.D. Vice President - Research
Age: 63
Kenneth M. Cohen Director
Age: 59
Robert E. Hoffman Director
Age: 48